Cingulate Inc.
Cingulate Inc.
- Market cap
- $24.31K
Your view on CINGW
Overview
What the company does, where it operates, and who runs it.
About Cingulate Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Shane J. Schaffer
- Headquarters
- 1901 West 47th Place, Kansas City, KS, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Shane J. Schaffer
- Headquarters
- 1901 West 47th Place, Kansas City, KS, US
Cingulate Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to pioneering therapies for central nervous system and neurobiological conditions.
Its leading investigational medicines are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), both designed to manage attention deficit/hyperactivity disorders (ADHD). Furthermore, the company is progressing CTx-2103 for the treatment of anxiety disorders.
Established in 2012, Cingulate Inc. maintains its main office in Kansas City, Kansas, and also operates a facility in Morristown, New Jersey.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Cingulate Inc.. Starting points for Cingulate Inc.: EPS -$5.37, beta -0.91 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Cingulate Inc.. Trailing twelve-month EPS for Cingulate Inc. stands at -$5.37. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Earnings per share estimates
| Per share | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | −$0.47 | −$0.40 | −$2.21 | −$1.81 |
| Lowest estimate | −$0.47 | −$0.40 | −$2.21 | −$1.81 |
| Highest estimate | −$0.47 | −$0.40 | −$2.21 | −$1.81 |
| Number of analysts | 1 | 1 | 1 | 1 |
| A year ago | −$0.961 | −$0.951 | −$4.131 | — |
| Growth vs a year ago | — | — | — | — |
1The year-ago figure includes one-time items, so growth is not shown.
Revenue estimates
| Total | This quarterDec 2026 | Next quarterMar 2027 | This yearYear to Dec 2026 | Next yearYear to Dec 2027 |
|---|---|---|---|---|
| Average estimate | $2.36M | $4.63M | $2.90M | $12.17M |
| Lowest estimate | $2.36M | $4.63M | $2.90M | $12.17M |
| Highest estimate | $2.36M | $4.63M | $2.90M | $12.17M |
| Number of analysts | 5 | 3 | 5 | 5 |
| A year ago | $0.00 | $0.00 | $0.00 | — |
| Growth vs a year ago | — | — | — | — |
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Cingulate Inc.. Cingulate Inc. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Industry | Mkt cap |
|---|---|---|---|---|---|
| APVOAptevo Therapeutics Inc. | Healthcare | Biotechnology | $883,709 | ||
| BOLTBolt Biotherapeutics, Inc. | Healthcare | Biotechnology | $12.8M | ||
| COCPCocrystal Pharma, Inc. | Healthcare | Biotechnology | $18.3M | ||
| ERNAErnexa Therapeutics Inc. | Healthcare | Biotechnology | $2.3M | ||
| EVGNEvogene Ltd. | Healthcare | Biotechnology | $2.7M | ||
| INABIN8bio, Inc. | Healthcare | Biotechnology | $8.2M | ||
| KALAKALA BIO, Inc. | Healthcare | Biotechnology | $1.7M | ||
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| AZTRAzitra, Inc. | Healthcare | AMEX | $3.1M | ||
| BBIOBridgeBio Pharma, Inc. | Healthcare | NASDAQ | $14.8B | ||
| BBIXFBonus BioGroup Ltd. | Healthcare | OTC | $157.7M | ||
| BBLGBone Biologics Corporation | Healthcare | NASDAQ | $909,962 | ||
| BBLGWBone Biologics Corporation | Healthcare | NASDAQ | $1.5M | ||
| BBOTBridgeBio Oncology Therapeutics Inc. | Healthcare | NASDAQ | $145.3M | ||
| BBTXBambusa Therapeutics Inc. | Healthcare | NASDAQ | $815.1M | ||
| BCABBioAtla, Inc. | Healthcare | NASDAQ | $2.9M | ||
| BCAXBicara Therapeutics Inc. Common Stock | Healthcare | NASDAQ | $560.3M | ||
| BCDABioCardia, Inc. | Healthcare | NASDAQ | $11.9M | ||
| BCHMFBachem Holding AG | Healthcare | OTC | $4.5B | ||
| BCLIBrainstorm Cell Therapeutics Inc. | Healthcare | OTC | $6.8M | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold Cingulate Inc., and how their positions are changing. At a $24,313 market value, institutional positions materially move Cingulate Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Cingulate Inc. executives and directors. Shares of Cingulate Inc. have traded between $0.0093 and $0.04 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Cingulate Inc.. Coverage tracks Cingulate Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Cingulate Inc.